Click on image to view larger version.

Figure 8 Comparison of the Incremental Risk of VLST in DES in Recently Published Studies With the Threshold Risk

The difference in observed yearly rates of VLST for sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES), versus BMS, are shown as point estimates taken from the recent pooled analyses (confidence intervals not shown) (10,12). The DES versus BMS differences fall just below the VLST threshold we identified (0.14%/year), signifying preserved overall benefit of DES versus BMS; however, a small absolute increase in DES VLST would exceed the threshold above which no net benefit would exist for DES over BMS. Abbreviations as in Figures 1 and 2.